循环中低水平密度的中性粒细胞与头颈部鳞状细胞癌对 PD-1 免疫治疗的耐药性相关。

Circulating low density neutrophils are associated with resistance to anti-PD1 immunotherapy in squamous head and neck cancer.

机构信息

Oncobiona Group, Navarrabiomed, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.

Medical Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain.

出版信息

Head Neck. 2023 Dec;45(12):3075-3085. doi: 10.1002/hed.27536. Epub 2023 Oct 4.

DOI:10.1002/hed.27536

PMID:37792371

Abstract

BACKGROUND

Identification of predictive biomarkers to Immune checkpoint inhibitors (ICIs) in head and neck cancer (HNSCC) is an unmet need.

METHODS

This was a prospective observational study including 25 patients with HNSCC treated with immunotherapy or chemotherapy after a prior platinum-based regimen. Low density neutrophils (LDNs) and serum markers were analyzed.

RESULTS

In the immunotherapy cohort, patients with high LDN levels had a shorter progression free survival (PFS) (1.8 months vs. 10.9 months; *p = 0.034). Also, progressors showed higher percentage of LDNs compared to non-progressors although significance was not reached (mean 20.68% vs. 4.095%, p = 0.0875). These findings were not replicated in patients treated with chemotherapy. High levels of interleukin-7 (IL7) were correlated with a significantly longer overall survival (OS) (13.47 months 3.51 vs. months, *p = 0.013).

CONCLUSIONS

High baseline circulating LDNs and low IL7 could identify a subset of patients intrinsically refractory to ICIs as monotherapy in HNSCC.

摘要

背景

识别头颈部癌症（HNSCC）中免疫检查点抑制剂（ICIs）的预测生物标志物是未满足的需求。

方法

这是一项前瞻性观察性研究，包括 25 例先前接受过铂类方案治疗后接受免疫治疗或化疗的 HNSCC 患者。分析低密度中性粒细胞（LDN）和血清标志物。

结果

在免疫治疗组中，LDN 水平较高的患者无进展生存期（PFS）较短（1.8 个月 vs. 10.9 个月；*p=0.034）。此外，进展患者的 LDN 百分比高于非进展患者，但未达到统计学意义（平均值 20.68% vs. 4.095%，p=0.0875）。这些发现在接受化疗的患者中没有得到复制。高水平的白细胞介素-7（IL7）与总生存期（OS）显著延长相关（13.47 个月 vs. 3.51 个月，*p=0.013）。